Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Colorectal Neoplasms 8Melanoma 6Colonic Neoplasms 4Rectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Solid Tumors 1Skin Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasms 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Disease Progression 1Digestive System Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 8cemiplimab 5Nivolumab 4Ipilimumab 4Blood Specimen Collection 3lifileucel 2avelumab 2aldesleukin 2Niacinamide 2Cyclophosphamide 2toripalimab 1tislelizumab 1oxycodone-acetaminophen 1lenvatinib 1fludarabine 1epacadostat 1encorafenib 1durvalumab 1dostarlimab 1brodalumab 1binimetinib 1atezolizumab 1Vitamin A 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Specimen Handling 1Resistance Training 1Radiotherapy 1Niacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × encorafenib × 90 days × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡